These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12010866)

  • 1. A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk.
    Gsur A; Preyer M; Haidinger G; Schatzl G; Madersbacher S; Marberger M; Vutuc C; Micksche M
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):497-8. PubMed ID: 12010866
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between the Met326Ile polymorphism of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase and prostate cancer risk: a prospective study.
    Paradis AE; Kantoff PW; Giovannucci E; Stampfer MJ; Ma J
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):172-3. PubMed ID: 12582030
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
    Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
    Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
    Binnie MC; Alexander FE; Heald C; Habib FK
    Prostate; 2005 Jun; 63(4):309-15. PubMed ID: 15599941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
    Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of UDP-glucuronosyltransferase 1A7 gene: a possible new risk factor for lung cancer.
    Araki J; Kobayashi Y; Iwasa M; Urawa N; Gabazza EC; Taguchi O; Kaito M; Adachi Y
    Eur J Cancer; 2005 Oct; 41(15):2360-5. PubMed ID: 16143514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
    Sun J; Wiklund F; Hsu FC; Bälter K; Zheng SL; Johansson JE; Chang B; Liu W; Li T; Turner AR; Li L; Li G; Adami HO; Isaacs WB; Xu J; Grönberg H
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):480-5. PubMed ID: 16537705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
    Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
    Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL; Abrahamsson PA; Giwercman A; Gadaleanu V; Ahlgren G
    Eur Urol; 2005 Oct; 48(4):679-85. PubMed ID: 16039774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer.
    Jacobsen NR; Nexø BA; Olsen A; Overvad K; Wallin H; Tjønneland A; Vogel U
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):584-5. PubMed ID: 12815008
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
    Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
    Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma.
    Yu C; Lu W; Tan W; Xing D; Liang G; Miao X; Lin D
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):176. PubMed ID: 12582032
    [No Abstract]   [Full Text] [Related]  

  • 16. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age.
    Tseng CS; Tang KS; Lo HW; Ker CG; Teng HC; Huang CS
    Am J Gastroenterol; 2005 Aug; 100(8):1758-63. PubMed ID: 16086712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.
    Singal R; Ferdinand L; Das PM; Reis IM; Schlesselman JJ
    Int J Oncol; 2004 Nov; 25(5):1465-71. PubMed ID: 15492840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population.
    Aktas D; Hascicek M; Sozen S; Ozen H; Tuncbilek E
    Cancer Genet Cytogenet; 2004 Oct; 154(1):81-5. PubMed ID: 15381379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility.
    Lai J; Kedda MA; Hinze K; Smith RL; Yaxley J; Spurdle AB; Morris CP; Harris J; Clements JA
    Carcinogenesis; 2007 May; 28(5):1032-9. PubMed ID: 17151093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mtDNA mutation on tumor malignant degree in patients with prostate cancer.
    Yu JJ; Yan T
    Aging Male; 2010 Sep; 13(3):159-65. PubMed ID: 20136572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.